Use of Beta-antagonists or HMG-CoA Reductase Inhibitors for Cardioprotection During Chemotherapy in Oncology Patients by Streich, Nicole
University of North Dakota
UND Scholarly Commons
Physician Assistant Scholarly Project Posters Department of Physician Studies
2019
Use of Beta-antagonists or HMG-CoA Reductase
Inhibitors for Cardioprotection During
Chemotherapy in Oncology Patients
Nicole Streich
University of North Dakota
Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Oncology Commons, and the Pharmaceutical Preparations Commons
This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.
Recommended Citation
Streich, Nicole, "Use of Beta-antagonists or HMG-CoA Reductase Inhibitors for Cardioprotection During Chemotherapy in
Oncology Patients" (2019). Physician Assistant Scholarly Project Posters. 155.
https://commons.und.edu/pas-grad-posters/155
Use of beta-antagonists or HMG-CoA reductase inhibitors for cardioprotection during 
chemotherapy in oncology patients
Nicole Streich, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Abstract
Discussion
 Anthracycline chemotherapy along with some other antineoplastic drugs 
such as taxanes, alkylating agents, small molecule tyrosine kinase 
inhibitors, and trastuzumab may lead to cardiotoxicity presenting as 
arrhythmias, heart failure, ischemic injury, or cardiomyopathy.
 Cardiac function is monitored before, during, and after treatment. 
Unfortunately, there are no recommendations for prevention of 
chemotherapy-induced cardiotoxicity at this time. 
 Whether a patient is just starting their chemotherapy regimen or is five 
years post-treatment, all healthcare providers should make sure to do a 
thorough cardiac exam to rule out any residual damage from the 
chemotherapy.  
 Until further research is done regarding the use of beta-antagonists or 
HMG-CoA reductase inhibitors for prevention of chemotherapy-induced 
cardiotoxicity, monitoring the patient’s cardiac function is very important. 
Healthcare providers need to be aware of the cardiotoxic effects that may 
result during or following antineoplastic therapy. It is important for 
providers to be aware of the side effects of these chemotherapeutic 
agents and assess these patients with these side effects in mind. 
Whether a patient is just starting their chemotherapy regimen or is five 
years post-treatment, providers should make sure to do a thorough 
cardiac exam to rule out any residual damage from the chemotherapy.  
Over the years, oncologists are better able to fight cancer and have 
increased cancer survival, but we are also finding that these lifesaving 
therapies can affect the heart and other parts of the body in a negative 
way. Chemotherapy is excellent at destroying cancer cells, but it also 
causes collateral damage to other healthy cells. There are certain 
chemotherapeutic agents that are known to cause cardiotoxicity. Currently 
we are monitoring the heart function of the patients who are receiving 
these cardiotoxic drugs prior to starting the chemotherapy as well as 
during and after treatment. However, there are currently no 
recommendations for what can be done to prevent the cardiotoxicity. The 
intention of this scholarly review is to look into the benefits and compelling 
results in adrenergic beta-antagonists and HMG-CoA-reductase inhibitors 
to reduce the risk of cardiotoxicity during chemotherapy in oncology 
patients. The goal of this paper is to look at the research and hopefully 
conclude that either beta-antagonists or hmg-CoA reductase are a reliable 
option to prevent chemotherapy-induced cardiotoxicity. An extensive 
literature review was performed and at this time, there are no concrete 
benefits of using either a beta-blocker or a statin to reduce chemotherapy-
induced cardiotoxicity. In the research that has been done, there is some 
evidence of using these agents to protect the heart. More long-term 
studies need to be conducted as well as more precise inclusion terms 
need to be used, such as the exact chemotherapy regimen or the 
particular cardioprotective medication that is used in the study. At this 
time, recommendations to prevent chemotherapy-induced cardiotoxicity 
remains inconclusive.
• Over the years, oncologists are better able to fight cancer and have 
increased cancer survival, but we are also finding out that these 
lifesaving therapies can affect the heart and other parts of the body in a 
negative way. Since chemotherapy is not able to target just the tumor, 
there is collateral damage to other cells throughout the body. This off-
target destruction can have external signs such as nausea, vomiting, 
and hair loss. There is also silent internal damage being done, 
sometimes to the heart and blood vessels. These injuries can appear 
immediately while receiving chemotherapy or at times the damage may 
not surface for years after treatment. There are not a lot of research 
studies available to look at what options can be done to protect the 
healthy cells from the effects of the chemotherapy. This is important to 
consider because of the negative effects that are being caused by the 
chemotherapy. The benefit of finding a cardioprotective agent for this 
population could help save the hearts and lives of many oncology 
patients.
• One of the most well known and most studied chemotherapeutic agents 
that is associated with adverse cardiac events are anthracyclines, such 
as doxorubicin. Anthracyclines are often used to treat adult 
malignancies such as breast cancer, sarcoma, lymphoma, or 
gynecological cancer. For many years, anthracycline-based 
chemotherapy has caused cardiotoxicity, attributing mostly to the 
creation of oxygen free radicals causing oxidative stress. More recent 
research has revealed that the mechanism for anthracycline 
cardiotoxicity is due to DNA damage from disruption. There are other 
chemotherapeutic agents associated with cardiotoxic side effects, 
which include, taxanes (paclitaxel, docetaxel), alkylating agents 
(carboplatin, cisplatin), small molecule tyrosine kinase inhibitors 
(lapatinib, imatinib), and trastuzumab which is a monoclonal antibody 
that is directed at the human epidermal growth factor receptor-2 
(HER2). Clinical manifestations of cardiotoxicity include many 
disorders, ranging from mild transient arrhythmias and heart failure to 
possibly deadly conditions such as myocardial infarction or ischemia 
and cardiomyopathy. 
• The intention of this scholarly review is to look into the benefits and 
compelling results of adrenergic beta-antagonists in reducing the risk of 
cardiotoxicity during chemotherapy in cancer patients. The goal is to 
look at the research and hopefully conclude that beta-antagonists are a 
reliable option for heart protection during antineoplastic treatment.
Research Question
In adult oncology patients, do either adrenergic beta-antagonists or HMG-
CoA-reductase inhibitors reduce the risk of cardiotoxicity in patients 
receiving chemotherapy? 
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Statement of the Problem
It is known that certain chemotherapeutic agents have the potential to lead 
to cardiac damage, but there is no known method to protect the heart cells 
from these drugs. Monitoring for damage prior to starting the chemotherapy 
treatment, during the course of treatment, and following the completion of 
treatment is already being done for patients that are receiving 
chemotherapeutic agents known to cause cardiotoxicity. Methods to 
prevent this myocardial damage are still being researched. In particular, 
research is being done to look at the benefit of using beta-antagonists or 
hmg-CoA reductase to prevent chemotherapy-induced cardiotoxicity. 
Adrenergic beta-antagonists or HMG-CoA-reductase inhibitors may be the 




Applicability to Clinical 
Practice
Chemotherapy agents can cause cardiotoxicity that can be seen as 
arrhythmias, heart failure, or cardiomyopathy. These effects can be seen 
throughout the course of chemotherapy or they can be seen months or even 
years following the completion of chemotherapy. 
HMG-CoA-reductase inhibitors 
 Protect the heart through anti-inflammatory and antioxidative mechanisms 
and have the potential to protect the heart from chemotherapy-induced 
cardiotoxicity. 
 Evidence may show that these may be beneficial to prevent chemotherapy-
induced cardiotoxicity, Sharalaya et al. (2018) and the article by Upshaw 
(2018). 
Adrenergic beta-antagonists
 Effect the heart by reducing spontaneous depolarization of pacemakers to 
cause continuation of sinus node cycle length, atrioventricular refractory 
period, and atrioventricular conduction times, Gorre et al. (2010). 
 Carvedilol may reduce diastolic heart failure and lower troponin I values 
leading to a decreased incidence of myocardial injury, Avila et al. (2018).
 beta-antagonists and ACE inhibitors may help preserve left ventricle ejection 
fraction in patients who are receiving the cardiotoxic anthracycline 
chemotherapy, Yun et al. (2015). This could be related to cardioprotective 
factors or it could be anthracycline dose dependent. 
The use of any pharmacological therapy to reduce chemotherapy-induced 
cardiotoxicity cannot yet be recommended. There is evidence that points to 
both HMG-CoA-reductase inhibitors and adrenergic beta-antagonists to be 
beneficial for cardioprotection. Until there is further research completed that 
looks at specific chemotherapeutic agents, specific hmg-CoA reductase or 
beta-antagonists, and long-term studies looking at heart function, no specific 
recommendations may be made to prevent chemotherapy-induced 
cardiotoxicity.
Etiology, prevalence, and outcomes of cardiotoxicity in adult patients 
receiving chemotherapy. 
 Cardiac toxicity has been related to many cytotoxic agents including; 
anthracyclines, anthraquinolones, antimetabolites, antimicrotubules, 
vinca alkaloids, and tyrosine-kinase inhibitors, Babiker et al. (2018). 
There is no consistency in how heart failure or cardiotoxicity is defined 
and there was varying degrees of heart function prior to starting therapy.
 Cardiotoxicity related to doxorubicin therapy is unusual in adults at 
cumulative doxorubicin doses less than 300 mg/m^2, and the rate of 
heart failure is approximately 7-26% at 550 mg/m^2 and at a rate of 
18-48% at a cumulative dose of 700 mg/m^2. Due to the potential of 
heart failure, there is a maximum lifetime cumulative dose of 
anthracyclines that is recommended. The recommended cumulative 
lifetime dose is 400-550 mg/m^2 for adults.
 Asymptomatic systolic or diastolic heart failure are the most common 
signs of chronic cardiotoxicity in cancer survivors, Chang et al. (2018). 
This makes close monitoring an essential step not only just during 
treatment but afterwards as well. Study limited by small sample size.
 The cumulative doxorubicin dose seems to be the best predictor of 
heart failure with a median dose of 390 mg/m^2 in the patients who 
developed heart failure and 180 mg/m^2 in those patients who did not 
develop heart failure. In patients who received greater than 400 
mg/m^2, the incidence of congestive heart failure was 3%, 7% in those 
patients that received 400-550 mg/m^2, and 18% in patients who 
received doses greater than 550 mg/m^2, Nathan et al. (2016) 
Limitations include varying comorbid health conditions.
 Volkova et all (2011) reported that heart failure prevalence seems to 
increase at a high cumulative dose of anthracycline therapy. Research 
is limited due to patients having different medical histories, varying 
cancer diagnoses, and diverse treatments. Table used to compare 
cumulative doxorubicin dose and percentage of patients with CHF. 
Prevention of chemotherapy-induced cardiotoxicity with the use of 
HMG-CoA-reductase inhibitors
 Patients (n = 40) undergoing anthracycline-based chemotherapy with 
mean EF for the statin group was unchanged before and after 
chemotherapy (61 +/- 8% versus 63 +/- 9%, p = 0.14) but was lower in 
the control group (63 +/- 7% versus 55 +/- 10%, p < 0.0001), Sharalaya 
et al. (2018). Limited by small sample size and no long-term follow-up.
 Anthracycline-based chemotherapy in female breast cancer patients 
(n = 628). This study showed that patients who received HMG-CoA 
reductase, 4 patients (6%) compared to the 27 patients (13%) in 
control group had a lower incidence of heart failure, Sharalaya et al. 
(2018).  
 Upshaw (2018) compared several medications to reduce chemotherapy 
induced cardiotoxicity. Most showed promise, including beta-
antagonists and HMG-CoA reductase inhibitors. This study was limited 
by using various medications in one specific class. 
 Riad et al. (2009) looked if fluvastatin pretreatment can attenuate 
doxorubicin-induced cardiotoxicity. The study was done in mice, not 
humans. 
 Results of the study showed that five days following the doxorubicin 
administration, untreated mice displayed significantly impaired systolic 
(LVP, −29%; dP/dtmax, −45%; P < 0.05), diastolic (dP/dtmin, −44%; 
stiffness, +275%; P < 0.05), and global left ventricle function (SV, 
−61%; HR, −18%; CO, −68%; P < 0.05) versus the placebo group. 
Therefore, Raid’s group concluded that using a statin, such as 
fluvastatin, to pretreat patients receiving doxorubicin therapy helps to 
prevent cardiotoxicity. 
Mechanism of action of adrenergic beta-antagonists
 Beta-antagonists influence the heart by decreasing spontaneous 
depolarization of pacemakers which causes prolongation of sinus node 
cycle length, atrioventricular refractory period, and atrioventricular 
conduction times, Gorre et al. (2010).
Prevention of chemotherapy-induced cardiotoxicity with the use of 
beta-antagonists
 Carvedilol to prevent anthracycline chemotherapy cardiotoxicity using 192 
Her2-negative breast cancer patients with normal LVEF, Avila et al. 
(2018). Study only looked at breast cancer patients in one cancer center. 
 Carvedilol did not affect early onset of LVEF reduction, but the 
carvedilol did have a significant reduction in troponin levels and 
diastolic dysfunction.
 Carvedilol 6.25 mg daily throughout chemotherapy in female breast 
cancer patients that were planning to receive doxorubicin chemotherapy, 
Beheshti et al. (2016). Study did not include any long term follow-up.
 There was a significant decrease in the control group (all p values 
<0.001). The mean differences of strain parameters in the case group 
were significantly less than the control group and also the strain-rate 
parameters. 
 Doxorubicin-induced cardiotoxicity can be reduced with carvedilol 
prophylaxis. 
 Efficacy of beta-antagonists and angiotensin antagonists to prevent left 
ventricular dysfunction and cardiac events in cancer patients receiving 
anthracycline chemotherapy, Yun et al. (2015). No long-term follow-up. 
Exact medications used were not reported.
 Association of angiotensin antagonists and beta-blocker therapy with 
high post-chemotherapy LVEF of 64.03% compared with 57.48% for 
control treatment.
 Experimental agents such as beta-antagonists and ACE-I, were seen 
to be more beneficial on LVEF preservation when the accumulative 
dose of anthracycline therapy was higher. 
Dose related risk of doxorubicin-induced congestive heart failure 
Volkova et al. (2011)
Cumulative Dose (mg/m^2) Patients with CHF (%)
150 0.2
300 1.6
450 3.3
600 8.7
